Talk track

Key Messages

  • SURGICEL™ is optimized for broad surface oozing.
  • Dual mechanism of action: induces vasoconstriction and activates the patient’s clotting cascade to achieve hemostasis.
  • SURGICEL™ Powder in made from 100% ORC composition; requires no preparation,† and achieves hemostasis in an average of 30 seconds, even after irrigation.
  • SURGICEL SNoW™ is a structured matrix for better conformability and retention at the bleeding site3,6 and has 43% faster hemostasis than SURGICEL™ Original.
  • SURGICEL SNoW™ is more effective than four layers of SURGICEL™ Original7 and is designed for trocar compatibility and ease of use.
  • Associated with up to 38% lower transfusion costs.
  • Only hemostat with proven in vitro antibacterial properties, including activity against antibiotic-resistant organisms.9-14,¶,||
  • Use of adjunctive hemostats like SURGICEL™ is linked to: reduced OR time, length of stay, transfusions, and readmissions.15-24

Detailed Talk Track

I noticed you selected TISSEEL® to manage the diffuse oozing encountered earlier in the case. While TISSEEL® is indicated for hemostasis in specific bleeding scenarios, it was originally designed for point-specific, targeted application. When it comes to broad surface oozing, a hemostat that can conform closely and act over a wide surface area may offer distinct advantages in both performance and efficiency. I’d like to introduce you to the SURGICEL™ family of absorbable hemostats, specifically SURGICEL™ Powder and SURGICEL SNoW™, which are optimized for managing continuous, diffuse bleeding across wide fields. These hemostats are made of oxidized regenerated cellulose (ORC) and function through a dual mechanism of action: they induce vasoconstriction and activate the patient’s intrinsic clotting pathway to form a stable clot.1-4 You mentioned workflow efficiencies are important, both SURGICEL™ Powder and SURGICEL™ Snow require no preparation† SURGICEL™ Powder achieves hemostasis in an average of 30 seconds, even after irrigation.*1-5 This makes it a rapid, efficient option that integrates seamlessly into your workflow. SURGICEL SNoW™ offers a unique structured matrix that conforms to complex anatomy, adheres to the bleeding site, and maintains its shape for better handling and trocar compatibility.3,6 It achieves 43% faster hemostasis than SURGICEL™ Original and outperforms even multiple layers of older-generation materials.3,6,7 Studies also show up to 38% lower transfusion costs with SURGICEL SNoW™.*8 Another consideration is infection risk. You mentioned your patients often have comorbidities and minimizing complications like SSIs is a priority. SURGICEL™ is the first and only hemostat with proven in vitro antibacterial properties against a wide range of pathogens, including antibiotic-resistant strains.9-14,¶,|| Finally, clinical evidence shows that adjunctive hemostats like SURGICEL™ are associated with reductions in OR time, hospital length of stay, transfusions, and readmission rates, which can impact both outcomes and resource use.15-24 Given the surface area of bleeding you encounter in these cases and the potential to simplify your process while maintaining reliable hemostasis, would you be open to evaluating SURGICEL™ Powder or SNoW™ in your upcoming cases where broad surface bleeding is expected?

References

*Compared to SURGICEL Original.

†Based on preclinical testing in a swine acute liver abrasion model

§17/21 surgeons agree (n=7) or strongly agree (n=10) that SURGICEL SNoW™ conforms better than SURGICEL™ Original. 19/19 surgeons agree (n=13) or strongly agree (n=6) that SURGICEL SNoW™ adheres to tissue better than SURGICEL™ Original.

¶The clinical benefit of these bactericidal claims has not been studied or demonstrated.

||In vitro compared to other TAH available in the US

1. MacDonald M. Pivotal study comparing performance of SURGICEL™ Powder—Absorbable Hemostatic Powder to ARISTA™ Absorbable Hemostatic Particles and PerClot® Polysaccharide Hemostatic System in a swine acute live biopsy model. Study 15-0120, Project 16438. September 2, 2015. Ethicon, Inc.

2. MacDonald M. Pivotal study comparing performance of SURGICEL™ Powder—Absorbable Hemostatic Powder to SURGICEL™ Original Absorbable Hemostat in a swine acute liver abrasion model. Study 15-0061, Project 16438. September 2, 2015. Ethicon, Inc.

3. SURGICEL™ Technical Report. 2018. Ethicon, Inc.

4. MacDonald M. Study comparing performance of SURGICEL™ Powder—Absorbable Hemostatic Powder to marketed competitive powdered topical hemostats in a swine acute liver abrasion model. Study 16-0006, Project 16438. March 8, 2016. Ethicon, Inc.

5. SURGICEL™ POWDER Absorbable Hemostat [Instructions for Use]. Ethicon, Inc.

6. Helms J. ETHICON™ biosurgery SNoW marketing claims
report. July 12, 2010. Ethicon, Inc.

7. Shnoda P. Project SNoW: Comparison of SURGICEL Non-Woven and SURGICEL™ ORIGINAL in the acute swine splenic incision hemostasis model. January 29, 2009. Ethicon, Inc.

8. Martyn D, Kocharian R, Lim S, et al. Reduction in hospital costs
and resource consumption associated with the use of
advanced topical hemostats during inpatient procedures. J
Med Econ. 2015;18(6):474481.

9. SURGICEL® ORIGINAL, SURGICEL® NU-KNIT®, SURGICEL® FIBRILLAR™ Instructions For Use. Ethicon, Inc

10. SURGICEL® SNoW™ Instructions For Use. Ethicon, Inc.

11. SURGICEL® Powder Instructions For Use. Ethicon, Inc.

12. Spangler D, Rothenburger S, Nguyen K, Jampani H, Weiss S, Bhende S, In Vitro Antimicrobial Activity of Oxidized Regenerated Cellulose Against Antibiotic-Resistant Microorganisms. Surgical Infections. 2003;4(3): 255-262.

13. Dineen P. The effect of oxidized regenerated cellulose on experimental infected splenotomies. J Surg Res 1977;23:114-116

14.SURGICEL™ Absorbable Hemostat. Full Prescribing Information, Ethicon, Inc.

15. Ferko N, Lee JM, Serebruany V, et al. A systematic approach to surgical hemostat use. JNJ Institute. 2017.academia.edu+1jnjinstitute.com+1

16. Martyn D, Kocharian R, Lim S, et al. Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures. Journal of Medical Economics. 2015. jnjmedtech.com

17. Hennegan K, Silber A, Yuan A, et al. HEOR study comparing clinical and economic outcomes of patients undergoing gynecologic surgery using SURGICEL™ Powder Absorbable Hemostat vs ARISTA™ Absorbable Hemostat. ISPOR Presentation. May 18–20, 2020. jnjmedtech.com+1news.thomasnet.com+1

18. Ethicon. New absorbable adjunctive hemostat from Ethicon helps surgeons control disruptive bleeding more efficiently. BioSpace. 2017. biospace.com+1news.thomasnet.com+1

19. Ethicon. SURGICEL® Powder Absorbable Hemostat is used in surgeries. ThomasNet News. 2017.news.thomasnet.com+1biospace.com+1

20. Ethicon. Retrospective study shows SURGICEL® family of topical absorbable hemostats decreases hospital resource use and lowers associated costs. PR Newswire. 2014. prnewswire.com

21. Shah T, Brethauer S, Danker WA III, et al. Implementation of a cost and variation reduction program for hemostasis products at a large academic medical center: a multi-stakeholder perspective. Medical Devices: Evidence and Research. 2025;18:63–73. dovepress.com

22. Ethicon. A systematic approach to surgical hemostat use. Academia.edu. 2017.mdpi.com+2academia.edu+2jnjinstitute.com+2

23. Ethicon. SURGICEL® Powder in knee osteoarthritis. ICH GCP Clinical Trials Registry. 2025. ichgcp.net

24. Ethicon. Clinical and applied safety and hemostatic effectiveness of SURGICEL® Powder. SAGE Journals. 2023.

CONFIDENTIAL. FOR INTERNAL USE ONLY. NOT FOR USE WITH ANY CUSTOMER OR FOR EXTERNAL DISTRIBUTION.

Close

Click for assets
SURGICEL™ Resources